title: Potential drug-drug interactions at a referral hematology-oncology ward in Iran: a cross-sectional study.
abstract: OBJECTIVE
  To assess the pattern and probable risk factors for moderate and major drug-drug interactions in a referral hematology-oncology ward in Iran.
  
  
  METHODS
  All patients admitted to hematology-oncology ward of Dr. Shariati Hospital during a 6-month period and received at least two anti-cancer or non-anti-cancer medications simultaneously were included. All being scheduled anti-cancer and non-anti-cancer medications both prescribed and administered during ward stay were considered for drug-drug interaction screening by Lexi-Interact On-Desktop software.
  
  
  RESULTS
  One hundred and eighty-five drug-drug interactions with moderate or major severity were detected from 83 patients. Most of drug-drug interactions (69.73 %) were classified as pharmacokinetics. Fluconazole (25.95 %) was the most commonly offending medication in drug-drug interactions. Interaction of sulfamethoxazole-trimethoprim with fluconazole was the most common drug-drug interaction (27.27 %). Vincristine with imatinib was the only identified interaction between two anti-cancer agents. The number of administered medications during ward stay was considered as an independent risk factor for developing a drug-drug interaction.
  
  
  CONCLUSIONS
  Potential moderate or major drug-drug interactions occur frequently in patients with hematological malignancies or related diseases. Performing larger standard studies are required to assess the real clinical and economical effects of drug-drug interactions on patients with hematological and non-hematological malignancies.
authors.affiliation: Faculty of Pharmacy and Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran. hajibaba@tums.ac.ir
authors.forename: Molouk
authors.initials: M
authors.lastname: Hadjibabaie
authors.forename: Shirinsadat
authors.initials: S
authors.lastname: Badri
authors.forename: Sarah
authors.initials: S
authors.lastname: Ataei
authors.forename: Amir Hossein
authors.initials: AH
authors.lastname: Moslehi
authors.forename: Iman
authors.initials: I
authors.lastname: Karimzadeh
authors.forename: Ardeshir
authors.initials: A
authors.lastname: Ghavamzadeh
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D003627:Data Interpretation, Statistical; D004347:Drug Interactions; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology*; D005260:Female; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006748:Hospital Departments; D006785:Hospitals, University; D006801:Humans; D007492:Iran; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016522:Oncology Service, Hospital; D004364:Pharmaceutical Preparations / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D004364:Pharmaceutical Preparations